How to Reduce the Cost of Early-Onset Sepsis Diagnosis in Newborns

Recent Trends

Hospitals and health systems are increasingly adopting two approaches to lower the cost of early-onset sepsis (EOS) diagnosis in newborns: risk-stratified clinical pathways and rapid molecular diagnostics. Over the past few years, a growing number of centers have moved away from universal blood culture and broad-spectrum antibiotics toward targeted testing based on maternal and infant risk factors. This shift is partly driven by evidence that the incidence of culture-confirmed EOS is low—ranging roughly from 0.5 to 1 case per 1,000 live births—meaning many asymptomatic newborns receive unnecessary invasive procedures.

• Sepsis risk calculators (e.g., Kaiser Permanente and neonatal EOS calculators) now help clinicians decide whether to observe, perform lab work, or treat, reducing antibiotic days and length of stay.
• Multiplex PCR panels that can detect bacterial DNA in under two hours are gaining traction as a faster, potentially cheaper alternative to traditional blood cultures (which take 24–48 hours).
• Shorter empiric antibiotic courses (e.g., stopping at 36–48 hours if cultures remain negative) are being standardized to lower drug costs and minimize exposure.

Background

Early-onset sepsis—defined as infection occurring within the first 72 hours of life—is a serious but rare emergency. Diagnosis has traditionally relied on blood culture, a test that is sensitive but slow, and often accompanied by a complete blood count (CBC) with differential and C-reactive protein (CRP) measurements. Many hospitals also perform lumbar punctures in neonates with suspected sepsis. The cumulative cost of these tests, plus empirical intravenous antibiotics and prolonged NICU observation, can run from several hundred to several thousand dollars per infant, even when infection is not confirmed.

The challenge is balancing clinical safety with financial sustainability. A negative blood culture after 48 hours still carries hospital charges for the nursery stay, laboratory fees, and antibiotic administration. Meanwhile, the risk of missing a true infection is very low, but the medicolegal and emotional consequences are high. This tension has driven interest in more efficient diagnostic algorithms.

User Concerns

Parents and caregivers face both direct and indirect financial worries. These include:

• Hospital bills: Even for a healthy-appearing term infant admitted for observation, a two-day stay with basic labs can cost families out-of-pocket amounts that vary widely by insurance plan.
• Unnecessary procedures: Lumbar punctures and repeated blood draws are painful for the newborn and anxiety-provoking for parents, who may question whether they are medically needed.
• Insurance coverage: Some insurers require prior authorization for newer rapid tests or may not cover certain molecular panels until they are listed as in-network or medically necessary.
• Hospital variation: Parents may not know their hospital’s protocol. Centers with high antibiotic initiation rates may lead to longer separation from the baby and extra costs without clear benefit.

Likely Impact

If current trends continue, the financial burden of EOS diagnosis could drop noticeably in several ways:

• Lower average cost per screened infant: Risk-calculator use is projected to reduce the proportion of newborns receiving full lab evaluation by 30–50%, directly saving laboratory and pharmacy costs.
• Reduced NICU and observation charges: Infants deemed low-risk may be allowed to stay in the mother’s room (rooming-in) rather than being admitted to the NICU, cutting per-diem costs by hundreds of dollars per day.
• Shorter time to definitive answer: Rapid PCR tests can return a result within the same clinical shift, enabling earlier antibiotic discontinuation or earlier discharge when negative.
• Fewer lumbar punctures: When combined with a normal physical exam and negative rapid test, many algorithms now recommend against routine spinal tap, avoiding additional procedure fees and complication risks.

What to Watch Next

Several developments could shape the affordability landscape further:

• Updates to national guidelines: The American Academy of Pediatrics (AAP) and other bodies are expected to release refined recommendations that may endorse specific risk-stratification tools and rapid diagnostics more broadly.
• Reimbursement changes: Medicare and private payers are evaluating whether to bundle sepsis workup costs into a single episode of care, which could create financial incentives for efficient testing.
• Point-of-care molecular devices: Newer handheld or near-patient platforms that can test for sepsis markers (e.g., procalcitonin, cytokine patterns) in minutes are entering trials; if proven accurate, they could replace multiple lab steps.
• Data-sharing networks: Multi-hospital collaboratives that track outcomes from low-testing protocols (e.g., the Better Outcomes for Neonates initiative) will provide safety evidence that may persuade reluctant institutions to adopt cost-saving measures.